Puma Biotechnology Inc (PBYI): Price and Financial Metrics

Puma Biotechnology Inc (PBYI)

Today's Latest Price: $9.48 USD

0.12 (1.28%)

Updated Oct 22 4:00pm

Add PBYI to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 384 in Biotech

See all "A" rated Strong Buy stocks

PBYI Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for PBYI is 10.3 -- better than 97.02% of US stocks.
  • PBYI's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of 96.9% of US stocks.
  • Revenue growth over the past 12 months for Puma Biotechnology Inc comes in at -15.91%, a number that bests just 19.8% of the US stocks we're tracking.
  • If you're looking for stocks that are quantitatively similar to Puma Biotechnology Inc, a group of peers worth examining would be MOBL, MDB, MANH, DBX, and WIX.
  • PBYI's SEC filings can be seen here. And to visit Puma Biotechnology Inc's official web site, go to www.pumabiotechnology.com.

PBYI Stock Price Chart Interactive Chart >

Price chart for PBYI

PBYI Price/Volume Stats

Current price $9.48 52-week high $15.00
Prev. close $9.36 52-week low $5.50
Day low $9.33 Volume 524,900
Day high $9.56 Avg. volume 1,236,550
50-day MA $10.03 Dividend yield N/A
200-day MA $10.12 Market Cap 376.14M

Puma Biotechnology Inc (PBYI) Company Bio

Puma Biotechnology is a development stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of products for the treatment of various forms of cancer. The company was founded in 2010 and is based in Los Angeles, California.

PBYI Latest News Stream

Event/Time News Detail
Loading, please wait...

PBYI Latest Social Stream

Loading social stream, please wait...

View Full PBYI Social Stream

Latest PBYI News From Around the Web

Below are the latest news stories about Puma Biotechnology Inc that investors may wish to consider to help them evaluate PBYI as an investment opportunity.

Robbins Geller Rudman & Dowd LLP Announces Jury Verdict Finding Puma Biotechnology and CEO Alan Auerbach Committed Securities Fraud Results in Damages Three to Six Times Higher Than the Company Claimed

SAN DIEGO--(BUSINESS WIRE)--On September 8, 2020, a Court-appointed administrator confirmed the claims of more than 4,600 individual and institutional investors defrauded by Puma Biotechnology and its CEO, Alan Auerbach. The total damages these investors will recover, including pre- and post-judgment interest, exceed $55 million. Last year, a jury in the Central District of California found that both Puma Biotechnology and Auerbach committed securities fraud by making false and misleading state

Business Wire | September 8, 2020

Puma Biotechnology to Present at the H.C. Wainwright 22nd Annual Global Investment Conference

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology CEO Alan Auerbach will provide a company overview at the virtual H.C. Wainwright Global Conference on September 15, 2020.

Business Wire | September 8, 2020

Puma Bio: A Contrarian Investment That Requires Patience

Puma Biotechnology (PBYI) has been one of my more frustrating investments over the past year. I decided to take a stab at PBYI in Q4 of 2019 in anticipation the company was going to address NERLYNX’s tolerability and discontinuation rate. Well, the company has started to address these concerns and...

Biologics on Seeking Alpha | August 17, 2020

Puma Biotechnology, Inc. (PBYI) CEO Alan Auerbach on Q2 2020 Results - Earnings Call Transcript

Puma Biotechnology, Inc. (PBYI) Q2 2020 Earnings Conference Call August 6, 2020 16:30 ET Company Participants Mariann Ohanesian - Senior Director of Investor Relations Alan Auerbach - Chief Executive Officer, President & Chairman of the Board Jeff Ludwig - Chief Commercial Officer Maximo Nougues - Chief Financial Officer Conference Call...

SA Transcripts on Seeking Alpha | August 7, 2020

Puma Biotech (PBYI) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Puma Biotech (PBYI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo | July 30, 2020

Read More 'PBYI' Stories Here

PBYI Price Returns

1-mo -2.17%
3-mo -3.56%
6-mo -11.15%
1-year 32.22%
3-year -92.34%
5-year -89.21%
YTD 8.34%
2019 -57.00%
2018 -79.41%
2017 221.99%
2016 -60.84%
2015 -58.58%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.8587 seconds.